Table 3.

Summary of treatment-emergent adverse events in the all-abrocitinib cohort

	Abrocitinib 100 mg n (%)	Abrocitinib 200 mg n (%)
Patients evaluable for AEs	885	1971
Number of AEs	1968	4315
Patients with AEs	627 (70.8)	1420 (72.0)
Patients with SAEs	48 (5.4)	74 (3.8)
Patients with severe AEs	69 (7.8)	102 (5.2)
Deaths	1 (0.1)	2 (0.1)

AE adverse event, SAE serious adverse event.